Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fowler

Showing results (311-320 of 398) with videos related to

Pageof 40
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease PatientsLauren M Curtis, Filip Pirsl, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Archives of Toxicology|October 6, 2022
Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicantsF Jardi, C Kelly, C Teague, et al.
Bone Marrow Transplantation|April 24, 2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantationY Fløisand, L Brinch, T Gedde-Dahl, et al.
Haematologica|October 12, 2019
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patientsClaude Sportès, Nicole J McCarthy, Frances Hakim, et al.
Bone Marrow Transplantation|September 29, 2009
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)S A Mitchell, N Kline Leidy, K H Mooney, et al.
The Lancet. Diabetes & Endocrinology|July 19, 2016
Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trialJob G Godino, Gina Merchant, Gregory J Norman, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Pageof 40

Showing results (311-320 of 398) with videos related to

Sort By:
Pageof 40
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease PatientsLauren M Curtis, Filip Pirsl, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Archives of Toxicology|October 6, 2022
Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicantsF Jardi, C Kelly, C Teague, et al.
Bone Marrow Transplantation|April 24, 2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantationY Fløisand, L Brinch, T Gedde-Dahl, et al.
Haematologica|October 12, 2019
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patientsClaude Sportès, Nicole J McCarthy, Frances Hakim, et al.
Bone Marrow Transplantation|September 29, 2009
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)S A Mitchell, N Kline Leidy, K H Mooney, et al.
The Lancet. Diabetes & Endocrinology|July 19, 2016
Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trialJob G Godino, Gina Merchant, Gregory J Norman, et al.
Blood|June 5, 2008
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse populationSumithira Vasu, Susan F Leitman, John F Tisdale, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Pageof 40